Fig. 7: Role of del17p in tumorigenesis and therapy resistance/sensitivity.
From: Deletion of 17p in cancers: Guilt by (p53) association
A Summary of the role del17p plays in tumorigenesis. del17p is an early event where selection processes dictate expansion of the clone which, in turn, adds to therapy resistance and increased aggressive behaviour / metastatic potential. The inset list indicates the cancer types where del17p is associated with aggressive tumour behaviour and poor clinical outcome. CLL chronic lymphocytic leukaemia, MM multiple myeloma, AML acute myeloid leukaemia, DLBCL diffuse large B cell lymphoma, MCL mantle cell lymphoma, ALL acute lymphoblastic leukaemia, HCC hepatocellular carcinoma, CRC colorectal carcinoma. B Summary of the impact of del17p on malignant cell vulnerability and resistance to therapy. Vulnerability / Therapy resistance likely results from LOH and haploinsufficiency of the listed cell-essential genes or TSGs, respectively.
